Bio-Path Holdings Inc., (OTCQX: BPTH) (“Bio-Path”), a research and development company for cancer treatment, recently announced that its first two initial drug candidates have a market potential of more than $4 billion. With its recent value set at $0.35 a share and currently rising with a $22 million market cap, Bio-Path officials state they are poised for significant growth in 2013.
Apr 22, 2013 /prREACH/ -- March ?, 2012--HOUSTON, TX –Bio-Path Holdings Inc., (OTCQX: BPTH) (“Bio-Path”), a research and development company for cancer treatment, recently announced that its first two initial drug candidates have a market potential of more than $4 billion. With its recent value set at $0.35 a share and currently rising with a $22 million market cap, Bio-Path officials state they are poised for significant growth in 2013.
“Bio-Path is a great story,” Nielson said. “Investors looking for that high-growth portion of their portfolio should look at Bio-Path. We are coming very close to the milestones that will unlock the value of Bio-Path. The year 2013 is our inflection point with scientific evidence for delivery technology, proof of concept, plus a first drug with multi-billion dollar revenue potential.”
Liposomal Grb-2, Bio-Path’s lead cancer drug, is different from other cancer treatments because it uses a non-toxic lipid delivery technology in combination with antisense technology that blocks the production of the proteins in the cell that cause the cancer without killing the entire cell.
The drug is currently being tested in clinical trials on blood cancers, and many late stage cancer patients in the trial have stabilized their disease. In the first four cohorts completed there are also signs of anti-leukemia activity. Bio-Path is planning on developing the drug for triple negative and inflammatory breast cancer as well, which currently have no available treatments and have high mortality rates.
Grant Zeng, a Certified Financial Analyst, recently wrote on Zacks.com that Bio-Path stocks are now an attractive investment opportunity and are currently under-valued.
“We are especially impressed by the suggestion of possible anti-leukemia activity at the very low dosage, which was an unexpected and very positive result,” Zeng wrote. “We think Bio-Path’s stock should be trading around $1.00 per share, which values the Company at about $62 million in market cap.”
Bio-Path was founded with technology licensed from The University of Texas MD Anderson Cancer Center, the largest shareholder and maintains a strong working relationship with the cancer center. For more information on investment opportunities or treatments being developed, visit the company’s website http://www.biopathholdings.com
Any statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including Bio-Path's ability to raise needed additional capital on a timely basis in order for it to continue its operations, have success in the clinical development of its technologies, the timing of enrollment and release of data in such clinical studies and the accuracy of such data, limited patient populations of early stage clinical studies and the possibility that results from later stage clinical trials with much larger patient populations may not be consistent with earlier stage clinical trials, and such other risks which are identified in the Company's most recent Annual Report on Form 10-K and in any subsequent quarterly reports on Form 10-Q. These documents are available on request from Bio-Path Holdings. Any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Peter Nielsen President & Chief Executive Officer Tel 832-971-6616
Rhonda Chiger Institutional investors and Analysts 917-322-2569 [email protected]
Roger Pondel Individual and Retail Investors Pondel/Wilkinson Inc. 310-279-5980 [email protected]